In a pulmonary metastasis model of renal cancer, MAMs increase CCR5 but not CCR1 expression at the late stage of metastatic tumor development (by 21 days after tumor injection) and loss of Ccr5 but not Ccr1 reduces MAM accumulation in metastatic tumors at this time point (86). The gene discussed is CCR1; the disease is renal carcinoma.